Mirvetuximab soravtansine (mirvetuximab soravtansine-gynx; Elahere™)是一种抗体药物结合物（ADC），由叶酸受体α（FRα）定向抗体与微管抑制剂通过可解除的连接剂结合而成。该ADC正在由ImmunoGen开发用于治疗表达FRα的癌症。2022年11月，mirvetuximab soravtansine在美国获得批准，用于治疗已接受1-3个先前系统治疗方案的FRα阳性、铂类耐药的上皮性卵巢、输卵管或原发性腹膜癌的成年患者。本文总结了mirvetuximab soravtansine开发的里程碑，导致了该药首次获得批准。© 2023。作者（们），在Springer Nature Switzerland AG的独家许可下。

Mirvetuximab soravtansine (mirvetuximab soravtansine-gynx; Elahere™) is an antibody-drug conjugate (ADC), which is comprised of a folate receptor α (FRα) directed antibody conjugated to a microtubule inhibitor via a cleavable linker. The ADC is being developed by ImmunoGen for the treatment of FRα expressing cancers. In November 2022, mirvetuximab soravtansine was approved in the USA for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens. This article summarizes the milestones in the development of mirvetuximab soravtansine leading to this first approval.© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.